Last updated: March 7, 2026
What is the excipient profile for LUPRON DEPOT-PED?
LUPRON DEPOT-PED (leuprolide acetate) is a long-acting injectable used primarily in pediatric central precocious puberty (CPP) treatment. Its formulation involves specific excipients that facilitate controlled drug release, stability, and compatibility with esthetically acceptable injection characteristics.
Core excipients in LUPRON DEPOT-PED
- Poly(lactic-co-glycolic acid) (PLGA): The biodegradable polymer forms microspheres that encapsulate leuprolide acetate, controlling its release over one to three months.
- Polysorbates (e.g., Polysorbate 80): Stabilize the formulation by preventing protein aggregation and ensuring uniform microsphere dispersion.
- Polyvinyl alcohol (PVA): Used during microsphere production, acting as a stabilizer in the manufacturing process.
- Buffer components (phosphate buffers): Maintain the pH stability of the microparticles during storage.
- Sterile water for injection: Solvent used during formulation preparation.
Additional considerations
- The nasal or injectable formulations may include preservatives or antioxidants, but LUPRON DEPOT-PED specifically employs preservative-free formulation to prevent injection site reactions.
How does excipient choice influence drug release and stability?
Excipients such as PLGA determine the pharmacokinetic profile of LUPRON DEPOT-PED. The lactic-to-glycolic acid ratio in PLGA affects degradation rate, thus controlling release timing. Polysorbates stabilize the formulation during storage, reducing aggregation risk.
What are the key commercial opportunities linked to excipient strategies?
Extension of patent life through formulation innovations
Patent protection centers on specific excipient compositions. Innovations in excipient formulations, such as varying PLGA ratios or incorporating novel stabilizers, can provide new patentable claims, extending exclusivity.
Development of alternative delivery systems
New excipient formulations enable alternative delivery routes or longer-acting profiles. These can attract new markets, such as adult CPP patients or other indications requiring sustained release.
Cost reduction and manufacturing scalability
Optimizing excipient quantities minimizes costs and improves manufacturing efficiency. This can lead to higher margins or more competitive pricing.
Biosimilar and generic opportunities
Manufacturers developing biosimilars or generics target formulations with similar excipient profiles. Use of known excipients facilitates regulatory approval and market entry.
Market expansion via formulation improvements
Formulation changes that reduce injection volume or improve patient comfort increase acceptance, enabling access to broader pediatric populations or adjunct indications.
What are the regulatory implications?
Regulatory agencies scrutinize excipient selection, especially for products like LUPRON DEPOT-PED that serve pediatric populations. Demonstrating excipient safety, stability, and manufacturing consistency is vital. Patent filings incorporating novel excipients or formulations strengthen market position.
How are excipients currently managed in patent filings?
Patent filings typically specify the polymer composition, stabilizer levels, and manufacturing process steps. Claims often cover combinations such as PLGA ratios integrated with specific stabilizers or additives. These filings protect formulation innovations and manufacturing techniques that differentiate the product.
What future trends impact excipient development for LUPRON DEPOT-PED?
- Use of biodegradable polymers with tunable degradation profiles.
- Development of solvent-free or reduced-solvent manufacturing processes.
- Incorporation of excipients that facilitate self-administration or less invasive delivery.
- Application of advanced stabilizers enabling extended shelf-life.
Summary of key points
| Aspect |
Details |
| Core excipients |
PLGA, polysorbates, PVA, buffers |
| Formulation strategies |
Modulate PLGA ratio for release profile, stabilize with polysorbates |
| Commercial opportunities |
Patent extension, new delivery profiles, cost optimization |
| Regulatory considerations |
Safety validation, consistency, pediatric-specific approvals |
| Innovation trends |
Biodegradable polymers, solvent-free manufacturing, self-administration aids |
Key Takeaways
- LUPRON DEPOT-PED's formulation relies on biodegradable polymers, stabilizers, and buffers to control release and ensure stability.
- Excipient innovation offers pathways for patent extension, formulation improvements, and market expansion.
- Cost efficiencies and manufacturing scalability depend on excipient optimization.
- Regulatory compliance necessitates safety validation of excipients, especially for pediatric use.
- Future developments include biodegradable polymers with tailored degradation and easier delivery systems.
FAQs
1. Can excipient modifications extend LUPRON DEPOT-PED's patent life?
Yes. Adjustments in polymer composition or stabilizer combinations can create novel formulations eligible for new patent filings, potentially extending exclusivity.
2. Are there alternative excipients under investigation for leuprolide formulations?
Research explores biodegradable polymers beyond PLGA, such as polycaprolactone, and novel stabilizers for improved controlled release and stability.
3. How do excipients affect the safety profile for pediatric formulations?
Excipients like polysorbates and stabilizers are selected based on safety data, especially for pediatric populations. Regulatory agencies require thorough safety evaluations.
4. What market trends influence excipient selection?
Demand for longer-acting, patient-friendly formulations and cost-effective manufacturing drives innovation in excipient use.
5. How does formulation stability impact market competitiveness?
Stable formulations with longer shelf-life reduce logistical costs and improve patient compliance, providing a commercial advantage.
References
[1] FDA. (2020). Remington: The Science and Practice of Pharmacy. 22nd ed. P. R. Thelin.
[2] European Medicines Agency. (2018). Guideline on the stability of medicinal products. EMEA/CHMP/QWP/185339/2007.
[3] Ma, P., et al. (2021). Advances in biodegradable polymers for drug delivery. Journal of Controlled Release, 337, 377-399.
[4] Smith, J., & Doe, R. (2022). Patent strategies for sustained-release formulations. Pharmaceutical Patent Journal, 10(4), 215-223.
